Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s (NYSE: BMY) entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 1.71%. On last trading day company shares ended up $51.82. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 2.51%.
GlaxoSmithKline PLC (ADR) (NYSE:GSK) said Friday a late stage study of its drug eltrombopag for the treatment of chronic immune thrombocytopenia in paediatric patients had met its primary endpoint. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares advanced 0.18% in last trading session and ended the day on $54.40. GSK gross Margin is 69.60% and its return on assets is 17.30%.GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is 1.25%.
Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced successful results from a Phase III study of experimental drug sarilumab in treating rheumatoid arthritis (RA) in patients who had previously shown no response to methotrexate (MTX) treatment. Sanofi SA (ADR) (NYSE:SNY) shares moved up 0.17% in last trading session and was closed at $53.69, while trading in range of $53.50 – $53.77. Sanofi SA (ADR) (NYSE:SNY) year to date (YTD) performance is 3.75%.
Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY) recently announced the acquisition of Genia Technologies in a bid to strengthen its diagnostics portfolio. Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) ended the last trading day at $37.37.
The HealthCare segment at Bayer AG (ADR) (OTCMKTS:BAYRY) announced that it has submitted a Marketing Authorisation Application for Eylea (aflibercept solution) for the treatment of patients suffering from visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). On last trading day company shares ended up $140.97.
Leave a Reply